- Elyes joined Andera Partners in 2018 as an analyst in the Andera Life Sciences team.
- Prior to joining Andera, Elyes gained a wide range of experience in the pharmaceutical industry (LFB, AstraZeneca).
- Elyes graduated from the Faculty of Pharmacy of the University of Paris-Sud and ESCP.
- He speaks Tunisian, French and English.
Investments of Elyes
New generation of antibody-based immunotherapy for the treatment of cancer and autoimmune diseases
Novel enzymatic therapy for solid and liquid tumours
Antibodies for the treatment inflammation in renal failure
Electrostimulation device for stress incontinence
Small molecule for the treatment of progressive multiple sclerosis
Platform of scaffold proteins oriented against intracellular targets in oncology
Development of novel treatments to combat multi drug-resistant bacterial infections